Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06291870

Predictors of Post-COVID-19 Clinical and Cognitive Consequences

The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Post Acute Sequelae of SARS CoV 2 Infection Apnea COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes Dyssomnias Fatigue Infections Lung Diseases Mental Disorders Nervous System Diseases Nidovirales Infections Obstructive Sleep Apnea Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post-Acute COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiration Disorders Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders Sleepiness Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

John D. Dingell VA Medical Center, Detroit, MI

Detroit, Michigan, 48201-1916, United States

Location status: Recruiting

Location contact

Ruchi Rastogi, MS

CONTACT

[email protected]

313-576-4464

Susmita Chowdhuri, MD MS

PRINCIPAL_INVESTIGATOR

About this study

This pilot study will systematically collect data to assess if sleep disturbances and severity of sleep apnea comprises a modifiable facet of PASC. This study will be the first step towards collecting preliminary data for a larger, longer-duration and more comprehensive study regarding the relationships between long-COVID and sleep disturbances which can inform future healthcare strategies and clinical decision-making. The study will also explore whether inflammatory biomarkers levels during acute COVID infection predict severity and duration of long-COVID or PASC and sleep fragmentation post-COVID.

Objectives: The overall goal of this project is to determine the associations between chronic post-COVID fatigue and sleep duration and sleep quality in patients after recovery from SARS-CoV-2 infection. The investigators have adopted the CDC definition for Post-COVID Conditions which persist for four or more weeks after SARS-CoV-2 infection and also is known as Post-Acute Sequelae of SARS-COV-2 infection (PASC).

Specific Aim 1: Determine associations between sleep duration and sleep quality on PASC-related fatigue symptoms, cognitive function, biomarker levels and vigilance.

Specific Aim 2. Determine if presence of obstructive sleep apnea (OSA) and level of PAP adherence during and prior to COVID-9 infection in patients with OSA predicts PASC- related fatigue, cognitive function and quality of life (QoL).

Exploratory Aim: Determine whether partial or full/booster vaccinations with COVID-19 mRNA vaccine vs. no vaccination has an impact on chronic post-COVID fatigue and sleep disturbances.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All individuals 18 years or older, with prior history of COVID-19 infection diagnosis
  • Both genders including all racial and ethnic groups
  • Patients with OSA (apnea hypopnea index of 5/hour on polysomnography) with history of COVID-19 infection will be eligible with prior history of COVID-19 infection and without COVID-19 for Aim 2

Exclusion criteria

  • Inability to give consent
  • Active suicidal symptoms
  • Children of all ages
  • Pregnant women

Treatment and study plan

Primary outcomes

  1. Neurocognitive function Trails A and Trails B

    Time frame: Change from baseline at 3 months

    Trails A and Trails B test will be administered to evaluate attention and psychomotor function. This score is adjusted for age, race, gender, and years of education. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.

  2. Neurocognitive function PASAT

    Time frame: Change from baseline at 3 months

    PASAT (Paced Auditory Serial Addition Test) will be administered to evaluate vigilance and executive function. The PASAT is recorded as the total number of correct responses (from 0-60), or the percent of correct responses out of 60 (from 0-100), where a higher value is a better outcome.

  3. Neurocognitive function Stroop color-word interference

    Time frame: Change from baseline at 3 months

    Stroop color-word interference test will be administered to evaluate executive function. This score is adjusted for age, and years of education. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.

  4. Neurocognitive function DIGIT

    Time frame: Change from baseline at 3 months

    DIGIT test will be administered to evaluate short-term and working memory. This score is adjusted for age. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.

  5. Neurocognitive function WASI

    Time frame: Change from baseline at 3 months

    Abbreviated Wechsler Abbreviated Scale of Intelligence (WASI) will be administered to evaluate verbal comprehension and working memory. This score is adjusted for age. Scored on a Standard scale of 100 +/- 15 for normal ranges, above 115 is above average, below 85 is considered below average.

  6. Neurocognitive function WMS

    Time frame: Change from baseline at 3 months

    Wechsler Memory test (WMS) will be administered to measure Verbal comprehension, and working and visual memory. Scored on a Standard scale of 100 +/- 15, where a higher score is a better outcome.

  7. Neurocognitive function PVT

    Time frame: Change from baseline at 3 months

    Psychomotor Vigilance Test (PVT) will be administered to measure Alertness and vigilance, in terms of number of lapses and reaction time. The performance score ranges from 0-100, where a higher value is a better outcome.

  8. Neurocognitive function HVLT-R

    Time frame: Change from baseline at 3 months

    Hopkins Verbal Learning Test - Revised (HVLT-R) will be administered to evaluate Verbal learning and memory. Scored on a Standard scale of 100 +/- 15, where a higher score is a better outcome.

  9. Sleepiness ESS

    Time frame: Change from baseline at 3 months

    Epworth sleepiness scale (ESS) score will be measured. This score is on a scale of 0-24, where a higher value indicates greater degree of sleepiness.

  10. Sleep quality PSQI

    Time frame: Change from baseline at 3 months

    Pittsburgh Sleep Quality Index (PSQI) is a detailed assessment of subject sleep quality over the most recent month by considering seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score to assess sleep quality on a scale of "poor" to "good".

  11. Quality of life SF-36v2

    Time frame: Change from baseline at 3 months

    QoL will be assessed using the survey SF-36v2 Health survey. Thirty-five of the SF-36v2 items are used to measure eight domains of health-related quality of life. These are on a scale of 0-100, where higher values indicate a better outcome.

  12. Quality of life FOSQ

    Time frame: Change from baseline at 3 months

    Disease specific QoL will be assessed using the Functional Outcomes of Sleep Questionnaire FOSQ/(FOSQ). There are 5 subscale domains of the FOSQ (General Productivity, Social Outcome, Activity Level, Vigilance, and Intimate Relationships and Sexual Activity). There all range from 0-20, where a higher value is a better outcome. The total FOSQ is the sum of these subscale domains and ranges from 0-100, where a higher value is a better outcome.

  13. Quality of life SGRQ

    Time frame: Change from baseline at 3 months

    Disease specific QoL will be assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ has three subscale domains (Symptoms, Activity, and Impacts), which range from 0-100, where a higher value indicates a worse outcome. The total SGRQ is the average of these subscale domains and is on a scale of 0-100, where a higher value is a worse outcome.

  14. Fatigue Severity

    Time frame: Change from baseline at 3 months

    Fatigue Severity Scale (FSS): FSS measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, interfering with work, family, or social life. Where a higher value is a worse outcome.

  15. PROMISE Sleep Disturbance

    Time frame: Change from baseline at 3 months

    Sleep disturbance short form assesses sleep disturbance over the past seven days.

  16. Horne and Osteberg Morningness/Eveningness Questionnaire

    Time frame: Change from baseline at 3 months

    Morningness/Eveningness Questionnaire measures the degree of which respondents are active and alert at certain times of the day. Scale is 1 to 5.

  17. Mini Mental State Examination (MMSE)

    Time frame: Change from baseline at 3 months

    Mini Mental State Examination (MMSE) is a simple way to quantify cognitive function and screen for cognitive loss. This score is on a scale of 0-30, a larger value is a better outcome.

  18. Borg Scale

    Time frame: Change from baseline at 3 months

    This measures the level of dyspnea during the 6 minute walk test. It is on a scale of 0-10, where a larger value is a worse outcome.

  19. Dyspnea: Six-minute walk test (6MWT) distance

    Time frame: Change from baseline at 3 months

    Participants are instructed to achieve maximal distance. There is no scale, but a larger value is a better outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Ruchi Rastogi, MS

CONTACT

[email protected]

(313) 576-4464

Sponsors and collaborators

Lead sponsor

VA Office of Research and Development

Fed

Collaborators

  • John D. Dingell VA Medical Center

Registry information

Official study title

Predictors of Post-COVID Clinical and Cognitive Consequences

Acronym: SCLC

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Mar 4, 2024
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.